Cancer and Gc-MAF
I’ve stated before that should intracellular failsafe procedures to ensure cell death collapse, it is the function of your immune system to destroy rapidly replicating cells. How does the immunes system do this? It takes a strong Th1 system –the predominant part of an immune response that kills invaders to attack a growing cancer mass. One type of cell in this Th1 response is called a macrophage. In destruction of cancer, the macrophage attaches to a binding receptor on a cancer cell and then activates to destroy the cell. With many types of cancer, an enzyme created by the growing cancer can halt this activation process. This is not good as it renders the immune response null and void.
A protein molecule circulating in the blood called Gc protein (also called Vitamin-D binding protein) is abundant in healthy individuals and aids in the destruction of pathogens and cancer cells. It is a glyco-protein, meaning that it has specific sugars attached to it that form something like a key. Found in human blood serum, Gc protein becomes the molecular switch to activate macrophages when it is converted to its active form called Gc-macrophage-activating-factor (Gc-MAF). Gc protein is normally activated by conversion to Gc-MAF with the help of the B and T cells (white blood cells in the immune response). Unfortunately, cancer cells get smarter over time and begin to secrete an enzyme known as alpha-N-acetylgalactosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to Gc-MAF, preventing the ‘last ditch’ macrophage protection against cancer. This is the way cancer cells escape detection and destruction - they disengage the immune system’s ability to kill the cancer. This also leaves cancer patients prone to infections and many then succumb to pneumonia or other infections, stuck in a Th2 dominant state.
I must also remind you that a suppressed immune system (from radiation or chemotherapy) leaves a similar result. Without a healthy immune response, a growing cancer is left on its own, unrestricted. This is why I’ll say it again:
You cannot kill cancer with chemotherapy, radiation and surgery alone! You MUST do other, immune stimulating therapies and search for the cause!
Understanding the above phenomenon, there is another promising way to stimulate the activation of a macrophage through the use of a nutrient called GcMAF. Taking GcMAF injections directly, activates the macrophage response thereby sharply stimulating a Th1 reaction that ‘turns-on’ macrophages.
Researchers testing GcMAF stated it, “works 100% of the time to eradicate cancer completely, and cancer does not recur even years later.” (This was stated based on the tested group of patients – nothing works 100% for everyone) The weekly injection GcMAF, a harmless glyco-protein activates the human immune system which then can kill the growing cancer. Studies among breast cancer and colon cancer patients produced complete remissions lasting 4 and 7 years respectively. This glyco-protein ‘cure’ is totally without side effect but currently goes unused and completely ignored by cancer doctors. Why? Maybe it is because there is little money to be made in selling it. For less than $2000USD a cancer patient can obtain an adequate amount of GcMAF.
The once-weekly injection of just 100 nanograms (billionths of a gram), can activate macrophages and allow the immune system to pursue cancer cells with vigor, sufficient to produce total long-term cures in humans. But remember, there is not one drug, medicine, herb, or nutriceutical that works for everyone. Everyone’s body is unique.
I just spoke to Dr. Nobuto Yamamoto, director of the Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania. He told me that GcMAF is “the most potent macrophage activating factor discovered yet oncologists ignore the research.” As I discussed a patient with him, he laughed at the treating oncologist’s demand for the patient to continue chemotherapy, “they don’t even know what they are doing,” he said, as he then pointed me to research data published in peer-reviewed Cancer journals from as far back as 1996 and as recent as 2008 that proved the benefits of GcMAF.
Unfortunately, there is too much money in chemotherapy!
How do you know if GcMAF will work for your cancer? There are a few ways to tell. A specialized medical lab test measuring Nagalase enzyme levels will reveal either normal (low) levels, indicating that GcMAF is not going to be your first choice, or abnormal (high), indicating GcMAF may be a perfect complement to help stimulate Th1 macrophage responses. One can also utilize kinesiology to easily test if GcMAF will potentially help a patient with cancer or measure other markers through blood.
NOTE: We do NOT sell GcMAF to NON-patients
Once a sufficient number of activated macrophages are produced, another Gc-MAF injection is not needed for at least a week because macrophages have a half-life of about six days. The studies revealed that after 16-22 weekly doses of Gc-MAF the amount of Nagalase enzyme fell to levels found in healthy people, which serves as evidence tumors have been completely eliminated. “The treatment was fool-proof - it worked in 100% of 16 breast cancer patients (tested) and there were no recurrent tumors over a period of 4 years,” says a report in the January issue of the International Journal of Cancer. [International Journal Cancer.2008 January15; 122(2):461-7]
In my conversations with Dr. Yamamoto, he kept telling me that he has always been “neutral” in the traditional vs. alternative cancer fight. He repeated that he just wished doctors would look at the facts. He and colleagues stated in an article published in Cancer Immunology Immunotherapy, “Gc-MAF therapy totally abolished tumors in 8 colon cancer patients who had already undergone surgery but still exhibited circulating cancer cells (possible metastases).” After 32-50 weekly injections, ”all (the tested) colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells,” said researchers, “an effect that lasted 7 years with no indication of cancer recurrence either by enzyme activity or CT scans.” [Cancer Immunology, Immunotherapy Volume 57, Number 7 / July 2008]
Though Dr. Yamamoto first described this immuno-therapy in 1993, [The Journal of Immunology, 1993 151 (5); 2794-2802] there are very few clinics utilizing the therapy.
In an animal experiment published in 2003, researchers in Germany, Japan and the United States collaborated to successfully demonstrate that after they had injected macrophage activating factor (Gc-MAF) into tumor-bearing mice, it totally eradicated tumors. [Neoplasia 2003 January; 5(1): 32–40] In 1997 Dr. Yamamoto injected GcMAF protein into tumor-bearing mice, with the same startling results. A single enzyme injection doubled the survival of these mice and just four enzyme injections increased survival by 6-fold. [Cancer Research 1997 Jun 1; 57(11):2187-92] In 1996 Dr. Yamamoto reported that all 52 cancer patients he had studied carried elevated blood plasma levels of the immune inactivating alpha-N-acetylgalactosaminidase enzyme (Nagalase), whereas healthy humans had very low levels of this enzyme. [Cancer Research 1996 Jun 15; 56(12):2827-31]
In the early 1990s, Dr. Yamamoto first described how the human immune system is disengaged by enzymes secreted from cancer cells, even filing a patent on the proposed therapy. [US Patent 5326749, July 1994; Cancer Research 1996 June 15; 56: 2827-31]
Activated Gc protein has been used in humans at much higher doses without side effect. This Gc macrophage activating factor (Gc-MAF) has been shown to be effective against a variety of cancers including breast, prostate, stomach, liver, lung, uterus, ovary, brain, skin, head/neck cancer, and leukemia. Although GcMAF is also called Vitamin-D binding protein, the activation of macrophages does not require Vitamin D (though many cancer patients are deficient).
GcMAF is a naturally made molecule and is not patentable (hence the reason why drug companies have ignored the data), though its manufacturing process is patent protected. One could argue that if an effective treatment for cancer would come into common practice, the income stream from health-insurance plans for treatment would collapse the medical monopoly in America. The National Cancer Institute estimates cancer care in the U.S. costs $100,000 to over a million dollars per year, per patient and produces only marginal improvements in survival. [Targeted Oncology 2007 April, 2 (2); 113-19]
The AMAS Test is another alternative to Nagalase Testing and is easier to obtain here in the United States. Its promoters state that the AMAS test is useful both as a screening test for early cancer and for monitoring cancer therapies. AMAS is elevated when cancer is present and goes down below baseline when cancer is undetected. They say it is over 99% accurate (when done twice) and can be used instead of Nagalase to find and follow cancers.
The AMAS test measures a naturally occurring antibody present in blood serum accurately detecting early cancer of all types. It will show positive if any type of cancer exists with greater than 95% accuracy; repeat testing greater than 99% accurate; false positive and false negative rates less than 1%. AMAS results will help monitor treatment choice as well as the numbers decrease with successful cancer treatment; normal levels in successfully treated cancer patients indicate absence of malignancy. I cannot promote the AMAS test personally though as I do not have experience using it and cannot find much data supporting it. That doesn’t mean that it is not valid; I would consider utilizing any newer test alongside current acceptable testing. It isn’t an expensive test and is sure worth the expense.